Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAP4K1 | Q92918 | 15/20 | 0.47 |
| ▸ | RPS6KA2 | Q15349 | 2/20 | 0.42 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.41 |
| ▸ | MEN1 | O00255 | 1/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.40 |
| ▸ | HTT | P42858 | 1/20 | 0.40 |
| ▸ | PPP1CA | P62136 | 1/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.40 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.40 |
| ▸ | CCNT1 | O60563 | 1/20 | 0.39 |
| ▸ | CDK9 | P50750 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8776232 | 0.91 | HTR7 (0.45) | L3MBTL1MEN1ALDH1A1HTTPPP1CA | |
| SCHEMBL8776105 | 0.87 | CYP1A2 (0.42) | L3MBTL1HTTSMN1; SMN2 | |
| SCHEMBL8775692 | 0.85 | SMN1; SMN2 (0.47) | L3MBTL1MEN1ALDH1A1HTTPPP1CA | |
| SCHEMBL8776618 | 0.85 | MAP4K1 (0.45) | MAP4K1RPS6KA2L3MBTL1MEN1KMT2A | |
| SCHEMBL8776365 | 0.82 | NPC1 (0.40) | L3MBTL1MEN1ALDH1A1PPP1CAKMT2A | |
| SCHEMBL8776077 | 0.82 | MAOA (0.44) | L3MBTL1MEN1ALDH1A1HTTPPP1CA | |
| SCHEMBL8775247 | 0.82 | ALDH1A1 (0.46) | L3MBTL1MEN1ALDH1A1HTTKMT2A | |
| SCHEMBL8776337 | 0.81 | L3MBTL1 (0.41) | L3MBTL1MEN1ALDH1A1HTTPPP1CA | |
| SCHEMBL8776017 | 0.81 | KCNH2 (0.45) | L3MBTL1MEN1ALDH1A1HTTPPP1CA | |
| SCHEMBL8775539 | 0.81 | L3MBTL1 (0.47) | RPS6KA2L3MBTL1MEN1ALDH1A1HTT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2012069652-A2 | FUNGICIDE MIXTURES | SYNGENTA PARTICIPATIONS AG (CH) | 2012-05-31 | — | — | WO | disclosed |
| US-20120129875-A1 | SUBSTITUTED QUINAZOLINES AS FUNGICIDES | SYNGENTA CROP PROTECTION, LLC (US) | 2012-05-24 | — | — | US | disclosed |
| WO-2010136475-A1 | SUBSTITUTED QUINAZOLINES AS FUNGICIDES | SYNGENTA PARTICIPATIONS AG (CH) | 2010-12-02 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120129875-A1 | SUBSTITUTED QUINAZOLINES AS FUNGICIDES | NAT1, NQO2, NOX1 | MAP4K1 1097/4885RPS6KA2 3743/4885L3MBTL1 3069/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.